About Us

연혁

Home기업소개연혁

ABL Bio History

ABL Bio 가 걸어온 발자취를 소개합니다.

ABL Bio

2019

  • 01

    No. 1 Biotech in Korea

  • 02

    Became the leader among biotech firms in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases using bispecific antibody.

2018

  • 06

    Series C Funding (paid-in capital of 70 billion KRW, June)

  • 07

    Multiple contracts on bispecific antibody program and technology transfer

  • 12

    IPO on KOSDAQ, Dec. 19, 2018 (90 billion KRW of public offering)

2017

  • 03

    Series B Funding (paid-in capital of 20 billion KRW, March)

  • 11

    ABL001 Clinical Trial Phase 1 (November)

2016

  • 02

    ABL Bio Established (February)

  • 03

    Series A Funding (paid-in capital of 9 billion KRW, March)